Trends and Updates in IBD
Appraising the Therapeutic Armamentarium in Moderate and Severe Disease
Physicians need further education to fully understand and implement current advanced therapies and distinguish the pathways of disease and targets addressed by newer therapies. This educational activity will provide key clinical data on new and emerging treatments, focusing on the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway in the context of evolving understanding of disease immunopathogenesis.
Jointly provided by Postgraduate Institute for Medicine and Integritas Communications.
This activity has been supported by independent educational grant from Gilead Sciences, Inc.
Snapshot of IBD Today
credit amount 0.25
credit type AMA PRA
expiration 08/23/2020
The Current and Emerging Treatment Landscape of IBD
credit amount 0.25
credit type AMA PRA
expiration 08/23/2020